ReviewInternational urology and nephrology2023
Frailty, sarcopenia and diabetic kidney disease: where do we stand?
Review in International urology and nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- The current state and development trends of frailty research in diabetic patients: a bibliometric analysis.Frontiers in medicine · 2025Pooled it
- Trial
- Frailty index and type 2 diabetes with renal complications: insights from Mendelian randomization and retrospective observational study.Renal failure · 2026Observational
- Visceral fat score predicts diabetic kidney disease: analysis of 20 years of U.S. NHANES data.Renal failure · 2026Article
- Mortality and persistence in therapy in elderly subjects with type 2 diabetes receiving gliflozins or incretins.Journal of endocrinological investigation · 2026Article
- Frailty in Focus: A Scoping Review of Frailty Instruments from the Kidney Disease Aging Research Collaborative.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Bidirectional association between sarcopenia and diabetic kidney disease: a prospective cohort study.BMC nephrology · 2026Article
- Comparison of two electronic medical record-based frailty assessment tools and their association with adverse outcomes in older hospitalized patients with urgent admissions.International journal of emergency medicine · 2025Article
- Review
- Paraspinal Muscle Fat Infiltration as a Key Predictor of Symptomatic Intravertebral Vacuum Cleft: A Machine Learning Approach.Journal of clinical medicine · 2025Article
- Menopausal Hormone Therapy in Women with Type 2 Diabetes Mellitus: An Updated Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Loop Diuretics and Sarcopenia: A Potential Association.Muscles (Basel, Switzerland) · 2023Review
- Sarcopenia and Tuberculosis: Is There Any Connection?Journal of personalized medicine · 2023Review
- Decreased Physical and Daily Living Activities in Patients with Peripheral Arterial Disease on Hemodialysis.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this narrative non-systematic review was to investigate the potential interplay among frailty syndrome, sarcopenia and diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM) patients. Data derived from a limited number of studies underline that DKD is a significant risk factor for frailty. On the other hand, frailty syndrome poses a higher risk for end-stage renal disease (ESRD) in subjects with DKD. In addition, frailty seems to affect the cognitive function and social life of DKD individuals, whilst as DKD deteriorates, there is a higher prevalence of sarcopenia which is a fundamental frailty factor. As a result, it is shown that a bidirectional relation is established between these entities, as diabetes mellitus (DM) affects the components of frailty and sarcopenia and vice versa. This vicious cycle is created through multiple pathophysiologic mechanisms, including the anabolic role of insulin, low-grade inflammation, cytokines and endothelial function, prompting further investigation in this area. Specific nutritional and exercise interventions are imperative to be established in order to ameliorate potential adverse outcomes, concerning these entities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.